Onyx Biotec IPO Details
IPO details Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.
| IPO Size | ₹29.34 Cr |
| Price Range | ₹58 - ₹61 |
| Retail Quota | 35.04% |
| QIB Quota | 49.89% |
| NII Quota | 15.07% |
| Employee Discount | -- |
| Listing at | NSE |
| Minimum Quantity | 2000 |
| Investment (cut-off price) | ₹122,000 |
| Pre IPO Promotor Holding | 88.60% |
| Post IPO Promotor Holding | Update soon |
| DHRP Draft | Click Here |
| RHP Draft | Click Here |
| Anchor Investors List | Click Here |
Onyx Biotec IPO Timelines
IPO Timelines Contrary to popular belief, Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old.
13/11/2024
Start Date18/11/2024
End Date20/11/2024
Refund Initiation20/11/2024
Credit of Shares to Demat Ac22/11/2024
Listing DateOnyx Biotec IPO Lot Size
IPO Lot Size There are many variations of passages of Lorem Ipsum available, but the majority have suffered alteration in some form, by injected humour, or randomised words which don’t look even slightly believable.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 2000 | ₹122,000 |
| Retail Maximum | 1 | 2000 | ₹122,000 |
| HNI Minimum | 2 | 4000 | ₹244,000 |
Onyx Biotec IPO Subscription Status
IPO Subscription Status Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
| QIB | NII | Retail | EMP | Total |
|---|---|---|---|---|
| 32.49x | 602.86x | 118.26x | -- | 198.00x |
IPO Performance on Listing Day
IPO Performance Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit.
| Opening Price | Closing Price | Day High | Day Low |
|---|---|---|---|
| ₹54.05 | ₹56.75 | ₹56.75 | ₹51.45 |
Onyx Biotec IPO Company Financials
ompany Financials At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint occaecati cupiditate non provident, similique sunt in culpa qui officia deserunt mollitia animi, id est laborum et dolorum fuga.
| Year | Total Income | Total Expense | PAT |
|---|---|---|---|
| FY 2022 | ₹44.98 | ₹41.19 | ₹3.35 |
| FY 2023 | ₹39.62 | ₹37.07 | ₹1.84 |
| FY 2024 | ₹53.87 | ₹49.82 | ₹3.03 |
| FY 2025 (2 M) | ₹10.54 | ₹8.79 | ₹1.31 |
About Company
Onyx Biotec Ltd., founded in 2005, is a leading pharmaceutical company specializing in generic and proprietary drugs, including sterile products like Water for Injection, Dry Powder Injections, and Syrups. Focused on accessibility and quality, the company provides affordable medications that aim to enhance patient health and well-being. Operating with two WHO-GMP-accredited facilities in Himachal Pradesh, Onyx Biotec upholds rigorous quality and safety standards.
Serving both domestic and international markets, Onyx Biotec has established itself as a trusted supplier in the sterile pharmaceutical sector, known for competitive pricing and high-quality offerings. The company plans to further enhance its capabilities with upgrades to its production and packaging units, aiming to improve efficiency and cost-effectiveness. Guided by experienced leadership, Onyx Biotec is committed to fostering strong client relationships and ensuring customer satisfaction through its adherence to ISO and GMP standards.
| Incorporation Date | Sector | Managing Director |
|---|---|---|
| 2005 | Healthcare | Sanjay jain |
Know Before Investing
Onyx Biotec IPO Strengths
- Top contract manufacturer specializing in sterile pharmaceutical production.
- Strict quality assurance and control processes maintain high product standards.
- Long-term relationships with leading pharmaceutical clients.
- Cost-efficient production focused on timely order fulfillment.
- Experienced management team with strong project management expertise.
Onyx Biotec IPO Risks
- Regional risks in Solan, Himachal Pradesh, may affect operations.
- Production disruptions could negatively impact financial stability and cash flow.
- Dependence on third-party suppliers introduces risks of supply delays or shortages.
- Reliance on key clients makes revenue vulnerable to losing major customers.
- Industry downturns could lead to reduced demand for products.
- Quality or delivery problems might result in order cancellations and financial losses.
Swot Analysis for Onyx Biotec IPO
Strengths
Market leader, Strong client relationships
Weaknesses
Financial losses, Domestic market dependence
Opportunities
Sector growth, Manufacturing capability enhancement
Threats
Intense competition, Regulatory compliance risks
Company Details
Onyx Biotec Limited
Bir Plassi Near Sainimajraropar,
Nalagarh Road, District Solan – 174101.
Phone: +91 172 265 6384
Email: generalinfo@onyxbiotec.com
Website: http://www.onyxbiotec.com/
IPO Registar Details
Mas Services Limited
Phone: (011) 2610 4142
Email: ipo@masserv.com
Website: https://www.masserv.com/opt.asp
FAQs
The key objectives of Onyx Biotec IPO are:
- Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use;
- Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections;
- Prepayment or repayment of all or a portion of certain loans availed by the Company; and
- General Corporate Purposes.
Horizon Management Private Limited is the book-running lead managers for the Onyx Biotec IPO.